NSCLC is often associated with targetable genetic alterations or predictive biomarkers such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, c-ros oncogene 1 (ROS1) rearrangements, v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutations, N-methyl-N′-nitroso-guanidine human osteosarcoma transforming gene (MET) exon 14 skipping mutations, rearranged during transfection (RET) rearrangement, Kirsten rat sarcoma viral oncogene homolog (KRAS), and neurotrophic tyrosine receptor kinase (NTRK) gene fusions [9, 10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.